HHS and FDA Send Thousands of Warning Letters to Drug Makers in Crackdown on Alleged Misleading Advertising
Agencies begin rulemaking to close a 1997 loophole after review found social media posts often omit safety risks; letters instruct firms to remove noncompliant promotions
The Department of Health and Human Services and the Food and Drug Administration on Tuesday sent thousands of warning letters to pharmaceutical companies as part of a campaign to curb what officials described as misleading drug advertising and to begin rulemaking to close a longstanding regulatory loophole.
Agency officials said the action targets a 1997 interpretation that they say has allowed some advertisers to promote benefits of prescription products in broadcast and digital ads while minimizing or omitting safety information. The letters, a commonly used first enforcement step under FDA procedures, direct companies to remove noncompliant advertising and bring promotional communications into compliance with federal law.
HHS Secretary Robert F. Kennedy Jr. and FDA Commissioner Marty Makary, M.D., M.P.H., issued statements saying the agencies will restore what they described as honesty and accountability in drug advertising. "Patients deserve the truth about the medicines they’re prescribed," Kennedy said. Makary said the FDA has for too long "permitted misleading drug advertisements, distorting the doctor-patient relationship and creating increased demand for medications regardless of clinical appropriateness." He added that drug makers spend as much as a quarter of their budgets on advertising and suggested those resources could be redirected to lowering prices.
A copy of one warning letter obtained by media outlets said the agency is concerned that "patients are not seeing a fair balance of the information regarding a drug product" and directed the recipient to remove any noncompliant advertising. The notices were distributed across the pharmaceutical industry and, according to sources familiar with the letters, include companies that run widespread direct-to-consumer campaigns such as Hims/Hers. Media outlets reported that companies were being notified on Tuesday afternoon; it was not immediately clear how many had formally responded.
The agencies pointed to a 2024 review in the Journal of Pharmaceutical Health Services Research finding that while nearly every pharmaceutical social media post highlights benefits, only about 33% mention potential harms. Federal regulators cite the Federal Food, Drug, and Cosmetic Act, enacted in 1938, as the statutory basis for regulating pharmaceutical advertising; the law grants the FDA authority to issue appropriate regulations, and agency officials say social media and broadcast advertisements fall within that remit.
FDA officials said the letters represent an initial enforcement step and that the agency may pursue additional action if companies do not comply. Under FDA practice, a warning letter typically asks firms to provide a response describing corrective actions. The agencies also said they plan rulemaking to more explicitly close the 1997 interpretation that critics say has permitted advertising that emphasizes benefits without an adequate presentation of risks.
Industry analysts said the move could prompt changes in how prescription products are marketed on television and digital platforms. Direct-to-consumer advertising has grown substantially since the late 1990s, and pharmaceutical promotion now commonly includes social media, influencer partnerships and targeted digital campaigns. Regulators and some clinicians have long debated the impact of direct advertising on prescribing, patient expectations and health-care costs.
Critics of current advertising practices have argued that incomplete presentations of risk can skew patient expectations and clinical conversations. Supporters of broader advertising flexibility contend that consumer information can prompt beneficial discussions with clinicians about treatment options. The agencies framed the letters as an effort to protect patients and rebuild public trust by ensuring promotional communications present a balanced view of benefits and risks.
The FDA and HHS did not specify a timeline for completing rulemaking, and the scope of any formal rule change will depend on the agencies’ regulatory process, which traditionally includes public notice and comment. The issuance of warning letters does not itself change the law but signals increased enforcement scrutiny as the agencies proceed with regulatory steps.
The agencies said they will monitor industry responses and take further action as necessary. Companies receiving letters typically have an opportunity to respond with planned corrective actions; the FDA may follow up with additional enforcement measures if it finds the responses inadequate. For now, the administration’s initiative sets a heightened enforcement posture on pharmaceutical promotion across traditional and digital media platforms.